Compare AP & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AP | ACHV |
|---|---|---|
| Founded | 1929 | N/A |
| Country | United States | United States |
| Employees | 1432 | N/A |
| Industry | Fluid Controls | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.2M | 172.0M |
| IPO Year | N/A | 2018 |
| Metric | AP | ACHV |
|---|---|---|
| Price | $10.12 | $4.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 154.6K | ★ 1.2M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.75 | $2.00 |
| 52 Week High | $12.30 | $6.15 |
| Indicator | AP | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 50.35 | 50.17 |
| Support Level | $9.12 | $4.65 |
| Resistance Level | $11.11 | $4.98 |
| Average True Range (ATR) | 0.92 | 0.42 |
| MACD | -0.26 | -0.11 |
| Stochastic Oscillator | 40.00 | 20.16 |
Ampco-Pittsburgh Corp manufactures and sells engineered, high-performance specialty metal products and customized equipment utilized by industry throughout the world. It operates in two business segments, namely the Forged and Cast Engineered Products segment and the Air and Liquid Processing segment. The Forged and Cast Engineered Products segment produces forged hardened steel rolls, cast rolls, and open-die forged products. Forged hardened steel rolls are used in cold rolling mills by producers of steel, aluminum, & other metals. The Air and Liquid Processing segment includes Aerofin, Buffalo Air Handling, & Buffalo Pumps. The company generates a majority of its revenue from the Forged & Cast Engineered Products segment. It has a business presence in the United States & other countries.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.